This effect is correlated with increased expression of the bone differentiation marker osteopontin, showing that BHQ880 is an anti-metastatic agent for osteosarcoma in a preclinical model [58] and is in phase 2 clinical studies for the treatment of multiple myeloma. The gene discussed is SPP1; the disease is AL amyloidosis.